ACS Medicinal Chemistry Letters

Patent Highlight

pubs.acs.org/acsmedchemlett

HDAC Inhibitors as Targeted Treatment of Frontotemporal Lobar Degeneration

Gerard Rosse*

Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States
Adjunct Associate Professor, Department of Pharmacology and Physiology, Drexel University, College of Medicine, New College Building, 245 N. 15th Street, Philadelphia, Pennsylvania 19102

Title:	HDAC Inhibitors as Targeted Treatment of Frontotemporal Lobar Degeneration		
Patent/Patent Application Number:	WO 2012135097 A1	**Publication Date:**	October 4, 2012
Priority Application:	US 2011-467989P	**Priority Date:**	March 26, 2011
Inventors:	Patzke, H.; Koenig, G.; Blain, J.-F.		
Assignee Company:	Envivo Pharmaceuticals, Inc., United States		
Disease Area:	Frontotemporal Lobar Degeneration (FTLD)	**Biological Target:**	Histone Deacetylases (HDACs)
Summary:	The application claims a series of benzooxazepine hydroxamic acids as potential treatment for Frontotemporal Dementia (FTD) or FTLD.		

Important Compound Classes:



Key Structures:



Compound 1

Recent Review Articles:	Cenik, B.; Sephton, C. F.; Dewey, C. M.; Xian, X.-D.; Wei, S.-G.; Yu, K.; Niu, W.-Z.; Coppola, G.; Coughlin, S. E.; Lee, S. E.; Dries, D. R.; Almeida, S.; Geschwind, D. H.; Gao, F.-B.; Miller, B. L.; Farese, R. V., Jr.; Posner, B. A.; Yu, G.; Herz, J. Suberoylanilide Hydroxamic Acid (Vorinostat) Up-regulates Progranulin Transcription: Rational therapeutic approach to frontotemporal dementia. *J. Biol. Chem.* **2011**, *286* (18), 16101−16108.
Biological Assays (Description):	Compounds were tested for their ability to modulate Progranulin levels in a variety of biological systems. No inhibitory activity of HDACs reported.
Pharmacological Data:	Compound **1** increases progranulin protein and RNA levels significantly in cells from human FTLD-PGRN mutation carriers.
Claims:	Claim 27: Use of compounds of the invention as potential treatment of FTLD

AUTHOR INFORMATION

Corresponding Author

*E-mail: grosse@dartneuroscience.com.

Notes

The author declares no competing financial interest.

Received: November 15, 2012
Published: November 30, 2012